|
|
|
|
|
|
|
|
|
|
|
|
|
22.10.26 - 11:24
|
Big pharma accused of ′free-riding on nature′ as global fund attracts just $7,000 (The Guardian)
|
|
|
The Cali Fund, set up to raise $1bn a year for biodiversity from drug companies, remains near emptyBig pharmaceutical companies have been accused of “free-riding on nature”, after a landmark biodiversity fund that invites businesses to put some of their profits back into conservation was left virtually empty.The Cali Fund set out to raise $1bn (£750m) annually, by asking companies that profit from nature's genetics to contribute towards conservation in low-income countries. But more than 18 months after the fund was launched, it remains far below this target. Continue reading......
|
|
|
|
|
|
|
|
|
|
|
22.10.26 - 04:16
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight (ZeroHedge)
|
|
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Authored by Paul D. Thacker via The DisInformation Chronicle,
New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers.
I'm not joking. This is the journalism I get for my paid subscription to the New York Times.
Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly.
But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...
|
|
|
|
|
21.10.26 - 23:00
|
Molina Healthcare Inc Q3 Income Retreats (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Molina Healthcare Inc (MOH) released a profit for third quarter that Drops, from the same period last yearThe company's bottom line totaled $38 million, or $0.73 per share. ......
|
|
|
|
|
|
|
|
|
|
|
21.10.26 - 03:06
|
China′s pharma stocks gain favours amid ′greater′ progress of innovative drugs (SCMP)
|
|
|
Chinese pharmaceutical companies are ramping up global expansion and the sector, set to sustain rapid growth with the upcoming third-quarter earnings releases, could see a further lift in market sentiment, analysts said.
In the first three quarters, domestic innovative drugs accounted for 80 per cent of all innovative medicines approved in China, according to the Ministry of Industry and Information Technology.
“Research progress has been made across multiple therapeutic areas including......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
